Quantumzyme Addresses OTC Markets Caveat Emptor Status and Unauthorized Promotional Activity
Biotechnology firm Quantumzyme is taking swift action to address its Caveat Emptor designation from OTC Markets and denounce unauthorized promotional text messages, demonstrating its commitment to regulatory compliance and market integrity.
Quantumzyme Corp., a biotechnology company specializing in computational enzyme engineering, is actively responding to its recent Caveat Emptor designation by OTC Markets Group. The company has immediately initiated contact with OTC Markets to understand and resolve the concerns leading to the designation.
CEO Naveen Kulkarni emphasized the company's dedication to regulatory compliance and market integrity. Quantumzyme has retained legal counsel to support a prompt resolution and is committed to working cooperatively with OTC Markets to remove the Caveat Emptor status.
Additionally, the company has strongly rejected any connection to recent unauthorized promotional SMS text messages mentioning Quantumzyme. The firm unequivocally denies any involvement, authorization, or prior knowledge of these communications and has pledged to fully cooperate with any potential regulatory reviews.
By proactively addressing these issues, Quantumzyme aims to protect its reputation and maintain transparent communication with shareholders and market stakeholders. The company remains focused on executing its business strategy and delivering long-term value to investors.